
==== Front
Cancer Immunol Immunother
Cancer Immunol Immunother
Cancer Immunology, Immunotherapy : CII
0340-7004
1432-0851
Springer Berlin Heidelberg Berlin/Heidelberg

39235633
3813
10.1007/s00262-024-03813-3
Correction
Correction to: Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells
El-Seraf Ibrahim i.elseraf@ajman.ac.ae

12
Nilsson Isabella Micallef 1
Moter Alina 1
Duan Zhe 1
Mattsson Jonas 13
Magalhaes Isabelle 14
1 https://ror.org/056d84691 grid.4714.6 0000 0004 1937 0626 Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
2 https://ror.org/01j1rma10 grid.444470.7 0000 0000 8672 9927 Basic Medical Sciences Department, College of Medicine, Ajman University, Ajman, UAE
3 grid.231844.8 0000 0004 0474 0428 Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation, Princess Margaret Cancer Centre and University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, ON Canada
4 https://ror.org/00m8d6786 grid.24381.3c 0000 0000 9241 5705 Department of Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden
5 9 2024
5 9 2024
11 2024
73 11 224© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ .
issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcCorrection to: Cancer Immunology, Immunotherapy (2024) 73:163 10.1007/s00262-024-03740-3

In the original version of this article, Fig. 2C and D labelling were incorrect. Figure 2 should have appeared as shown below.Fig. 2 Impact of treosulfan and fudarabine on spheroids tumor cells and on MSLN cell surface expression. A Viability of SKOV3 (parental or MSLN-transduced) spheroids cells after incubation for 48 h with treosulfan (50 µM), fudarabine (50 µM), or combination of fudarabine (25 µM) and treosulfan (50 µM) (n = 3). B Viability of OVCAR4 (parental or MSLN-transduced) spheroids cells after incubation for 48 h with treosulfan (50 µM), fudarabine (50 µM), or combination of fudarabine (25 µM) and treosulfan (50 µM) (n = 3). White bars: parental tumor cells; gray bars: MSLN-transduced tumor cells. C MSLN cell surface expression of MSLN-transduced SKOV3 cells after incubation for 48 h with treosulfan (25 µM) or fudarabine (25 µM) (n = 3). D MSLN cell surface expression of MSLNtransduced OVCAR4 cells after incubation for 48 h with treosulfan (25 µM) or fudarabine (25 µM) (n = 3). Exposure without drugs was used as negative control

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Isabella Micallef Nilsson and Alina Moter have contributed equally to this work.
